News of World Medicine


According to Phase 2 study presented at the congress of the European Academy of Dermatology and Venereology, the treatment of vitiligo patients with ruxolitinib cream caused a significant improvement in repigmentation (estimated as 50% or more of the baseline total vitiligo severity level) for 52 weeks . More than half of the patients, who applied the cream in the highest concentration twice a day, have restored more than half of the pigmentation on the face.

Ruxolitinib is a selective inhibitor of two Janus kinases (Janus Associated Kinases - JAKs), JAK1 and JAK2. These kinases contribute to the transmission of signals from numerous cytokines and growth factors, playing an important role in regulating the function of the immune system. Thus, the cream affects the pathogenesis of vitiligo, due to its effect on signaling pathway that provokes an immune response on melanocytes in such patients.

The first part of the study included 157 adults with vitiligo. They were randomly divided into several groups: the test group involved the adults used creams based on 1.5%, 0.5% or 0.15% of ruxolitinib once or twice a day, and the control group was a placebo (creams without an active substance).

The treatment continued for 24 weeks. The second part of the study included patients from the first phase, and lasted for additional 28 weeks. In total, the study lasted 52 weeks. The new remedy has demonstrated dose-dependent efficacy (ruxolitinib 1.5% twice a day). It is important that the cream was used without additional phototherapy. Researchers also noted that the face areas responded better to the therapy compared to the skin on the neck.